Maximising drug development with the latest on imaging application.
Successfully utilising molecular imaging technologies in preclinical and clinical drug development can provide vital information which drug candidates are likely to be successful and reveal candidates that are likely to fail, enabling early decision making to reduce time and costs.
Molecular imaging allows the non-invasive assessment of biological and biochemical processes in living subjects. With the potential to increase the understanding of diseases and how drugs affect the body, molecular imaging technologies used in preclinical and clinical drug development help to decide which drug candidates are likely to be successful and reveal candidates that seem likely to fail.
VIBevents Molecular Imaging in Drug Development conference, being held on 18 and 19 February 2009 in London, UK, will bring experts from the pharmaceutical and biotech industry together to discuss the latest developments in molecular imaging for preclinical and clinical drug development. Through a series of presentations, case studies and interactive discussions, participants learn new insight and gain hands-on experience in the latest trends and developments being used to drive and ensure success in this competitive environment.
Book now and ensure you attend those roundtables most relevant to you.
Visit www.medicalimaging-events.com for further details and to register.
We shall look forward to welcoming you in London!
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.